The cancer diagnostics market was valued at USD 55.7 billion in 2025 and is forecast to register an 8.5% CAGR between 2026 and 2036. In 2026, as oncology care needs procedure-ready sites, hospitals hold 48.0% of end user sales and blood samples represent 41.0% within the product type segment.